Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
News|Articles|November 10, 2015
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-12-02-2015
- Volume 11
- Issue 12
GRAM Adds Board Member
Author(s)Pharmaceutical Technology Editors
Industry veteran Mark Kontny joins board of directors at Grand River Aseptic Manufacturing.
Advertisement
The Grand River Aseptic Manufacturing (GRAM) announced on Nov. 10 2015 that industry veteran Mark Kontny was elected as a member of the the board of directors.
Most recently, Kontny served as president, Pharmaceutical Development Services and chief scientific officer for Patheon. Previously, he served as divisional vice president for Abbott Laboratories, responsible for divisional staffs in Illinois, Massachusetts, Germany, and Singapore. Earlier in his career, Mark spent 10 years at Boehringer Ingelheim, working with the pre-formulation, formulation, and manufacturing of different dosage forms. He became senior director at Pfizer and helped develop small molecules and biologics in both solid-dose and parenteral forms. He worked with a biotech start-up, prior to joining Abbott.
Articles in this issue
almost 11 years ago
Software Corrects Spectra Dataalmost 11 years ago
Lab Reactor Designed for Scale-upalmost 11 years ago
Instrument Measures Endotoxins at Point of Usealmost 11 years ago
Instrument Manufacturers Collaborate on Interoperabilityalmost 11 years ago
HTS Reader Features Three Light Sourcesalmost 11 years ago
“A Hit for Every Target” and Changing the Model for Pharma Innovationalmost 11 years ago
Researchers Identify Advances for Heterocyclic Chemistryalmost 11 years ago
CMOs Lead Ongoing Drive for Single-Use Adoptionalmost 11 years ago
System Automates Traceabilityalmost 11 years ago
Lufthansa Cargo Offers CSafe ContainersAdvertisement
Related to this article
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
The agency issued a direct final rule that supports the use of innovative testing methods to limit the use of animals and maintain existing safety standards.
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
Advertisement
Advertisement